JNJ · News · 20261019N
TREMFYA Crohn’s Disease Progress
JOHNSON & JOHNSON · 2026-10-19 · Importance 49 · Surprise 66 · In source text
Johnson & Johnson reported 48-week Phase 3 FUZION results for TREMFYA (guselkumab) in adults with Crohn’s disease and active perianal fistulas. Combined fistula remission was maintained or improved across both maintenance-dose regimens through Week 48. In the 100 mg dose group, remission increased from 28% at Week 24 to 35% at Week 48. The findings were presented at the 2026 United European Gastroenterology Week and support potential use in a difficult-to-treat Crohn’s disease manifestation.
Key facts
- In the 100 mg dose group, fistula remission increased from 28% at Week 24 to 35% at Week 48. source
- Johnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease. source
- TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens. source
- The late-breaking findings for TREMFYA were presented at the 2026 United European Gastroenterology Week (UEG Week). source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | In the 100 mg dose group, fistula remission increased from 28% at Week 24 to 35% at Week 48. |